Capability
Regulatory Strategy & FDA Pathways
Navigate FDA with Precision.
Regulatory strategy is not a checkbox — it is a commercial decision. The pathway you choose, the submissions you make, and the interactions you have with FDA directly affect your timeline, your label, your reimbursement eligibility, and your exit value. We help medtech companies build regulatory strategies that are aligned with their commercial goals from the start.
- 510(k) Strategy & Submission — Predicate identification, substantial equivalence analysis, and complete submission preparation.
- De Novo & PMA Pathways — Novel device classification strategy and premarket approval planning for higher-risk or breakthrough technologies.
- FDA Pre-Submission Meetings (Q-Sub) — Prepare for productive FDA interactions that clarify the path forward and reduce submission risk.
- Emergency Use Authorization (EUA) — Rapid-response regulatory support for time-critical situations.
- CE Mark & International Pathways — Regulatory strategy for EU MDR, Health Canada, and other international markets.
- Regulatory-Reimbursement Alignment — Ensure your indication statement, labeling, and clinical data support both regulatory clearance and payer coverage from day one.